$TMCI Cashflow Statement | Understand Stock

$TMCI

$4.55 +$0.13 (2.94%) Close

$TMCI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation and amortization expense
Provision for allowance for credit losses
Share-based compensation expense
Non-cash lease expense
Amortization of debt issuance costs
Impairment of capitalized surgical instruments
Gain on fair value adjustment to derivative liability
Provision for inventory obsolescence
Debt extinguishment loss
Loss on impairment of long-lived assets
Amortization (accretion) of premium (discount) on marketable securities, net
Other, net

Net changes in operating assets and liabilities, net of acquisitions:
Accounts receivable
Inventory
Prepaid expenses and other assets
Other non-current assets
Other liabilities
Operating lease liabilities
Accounts payable
Accrued liabilities
Other, net
Net cash provided by (used in) operating activities
Cash flows from investing activities
Purchases of available-for-sale marketable securities
Sales and maturities of available-for-sale marketable securities
Purchases of property and equipment
Acquisition, net of cash acquired
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from interest bearing term debt
Proceeds from insurance premium financing
Proceeds from interest bearing revolving debt
Debt issuance costs
Payments on interest bearing term and revolving debt
Payments on insurance premium financing
Payments on interest bearing debt
Proceeds from PPP Loan
Payments on PPP Loan
Proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of $7.5 million
Proceeds from exercise of employee stock options
Taxes from withheld shares
Net cash provided by (used in) financing activities

Net increase in cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Operating lease right-of-use assets obtained in exchange for new lease liabilities
Operating lease right-of-use asset and lease liability adjustment due to lease incentive
Noncash investing activities
Unrealized (gains) losses, net on marketable securities
Unsettled matured marketable security and receivable from broker
Noncash portion of internally developed software
Issuance of common stock upon exercise of warrants
Conversion of convertible preferred stock and accrued dividends on convertible preferred stock into common stock
Initial fair value of derivative liability

Noncash investing activities
Legal cost financing

Comments